SUBSCRIBE
SUBSCRIBE

Erlotinib Trumps Chemo in Advanced NSCLC With EGFR Mutations, Tongji University Study

October 12, 2010 | 
1 min read

MILAN (EGMN) –First-line erlotinib nearly tripled progression-free survival when compared with platinum-based chemotherapy in patients with advanced lung cancer carrying mutations activating the epidermal growth factor receptor.

Asia Europe
MORE ON THIS TOPIC
The EMA's former headquarters in London
Europe
Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Facade of AstraZeneca's office in Shanghai, China
Mergers & acquisitions
AstraZeneca Buys FibroGen’s China Unit for $160M as Probes Continue
February 20, 2025
 · 
2 min read
 · 
Tristan Manalac
Trendy halftone business concept collage. Idea concept, business concept, financial planning,financial profit, favorable conditions, favorable conditions. Trendy modern retro illustration in bright trendy colors. Vector illustration
Mergers & acquisitions
Bain Bets Big on Japanese Market With $3.3B Tanabe Buy
February 10, 2025
 · 
1 min read
 · 
Tristan Manalac
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
Rare diseases
AceLink’s Fabry Hopeful Shows Potential in Mid-Stage Study
February 10, 2025
 · 
2 min read
 · 
Tristan Manalac